

# MYOBLAST TRANSFER THERAPY FOR RELIEVING PAIN AND FOR TREATING BEHAVIORAL AND PERCEPTIVE ABNORMALITIES

## BACKGROUND OF THE INVENTION

5 The present invention relates to an approach for relieving pain and for treating behavioral and perceptive abnormalities, by using myoblast transfer therapy to provide a long-term, continuous supply of peptides in vivo that have analgesic activity.

10 Modern analgesia theory advanced significantly with a proposal by Pomeranz et al., *Exp. Neurol.* 54: 172 (1977), that a morphine-like, pituitary peptide mediates acupuncture analgesia. Electroacupuncture was found to reduce responses in spinal cord neurons to noxious stimuli in anesthetized cats and to increase squeak threshold in awake mice. The observed, prolonged time course implicated a hormonal mechanism for the response.

15 Spinal transaction, decerebration or hypophysectomy eliminated this acupuncture effect, and intravenous injections of naloxone, a morphine antagonist, also reduced it markedly.

20 These results indicate that electroacupuncture stimulates sensory nerves which activate the pituitary glands to release morphine-like hormones (peptides) effecting prolonged reduction in transmission along nociceptive pathways. This mechanism is believed to be a principal mediator of generalized and localized

25 analgesia.

Morphine-like peptides have been identified, and receptors to morphine-like peptides and to other opioid peptides have been found in the brain, the gut, the pituitary gland, the pancreas and the placenta. Hughes et al., *Nature* 258: 577 (1975); Pert et al., *Science* 179: 1011 (1979). These peptides now are known as  $\beta$ -endorphins and enkephalins. Cooper et al., *THE BIOCHEMICAL BASIS OF*

30

PHARMACOLOGY, 4th ed. (Oxford University Press, New York 1982). Furthermore, stimulation of brain neurons with an opioid peptide such as an endorphin produces analgesia. Fields et al., *Ann. Rev. Physiol.* **40**: 217 (1978). This effect can be reversed by naloxone.

Opioid peptides, especially  $\beta$ -endorphins, are essentially neural hormones or transmitters which reach all body tissue through diffusion. The presence of endorphin receptors in large numbers at different areas of the diencephalon and cerebral cortex suggests that the conjugate opioid peptides play a role in analgesia which goes beyond that of a simple modulator of pain perception. Covenas et al. *Neuropeptides* **30**: 261 (1996); Bernstein et al., *Neurosci. Lett.* **215**: 33 (1996); Bianchi et al., *Brain Res. Bull.* **40**: 269 (1996). Indeed, increases in cerebrospinal fluid and plasma levels of  $\beta$ -endorphins have been shown to modulate and optimize behavioral patterns exhibited in patients suffering from stress, psychiatric disorders, alcoholism, drug addition, obesity, and diabetes. Ryu et al., *Am. J. Chin. Med.* **24**: 193 (1996); Odagiri et al., *Int. J. Sports Med.* **17**: 325 (1996); Dalayeun et al., *Biomed. Pharmacother.* **47**: 311 (1993); Gianoulakis et al., *J. Psychiatry Neurosci.* **18**: 148 (1993). These increases also promote natural killer cell mediated cytotoxicity. Jonsdottir et al., *Regul. Pept.* **23**: 113 (1996); Sacerdote et al., *Regul. Pept.* **63**: 79 (1996).

Analgesia also is affected by binding of a pain mediator called "substance P" to its receptor. There are many similarities between the terminals of opioid neurons and the terminals of substance P sensitive neurons. For example, both types of terminals mediate pain sensation in the spinal cord. Jessel et al., *Nature* **268**: 549 (1977). As indicated, for example, in Japanese patent document JP 3133998, substance P receptors have been shown to act as analgesics by masking the activity of substance P. According to PCT application WO 92/16547, the NK-1 receptor preferentially binds substance P and

can be used to treat pain, inflammatory disease, mental illness and stress.

Patients afflicted with conditions such as stress, psychiatric disorders, alcoholism, drug addition, obesity, and diabetes may obtain some measure of relief from an above-normal level of endogenous opioid peptides in their plasma. Clinical relief of symptoms of these conditions have been associated with the binding of opioid peptides with their receptors, which is directly correlated with the level of opioid peptides in the patient's plasma and cerebrospinal fluid. Patients also may benefit from increased levels of substance P receptors or substance P analogs. See WO 92/16547, *supra*, and PCT application WO 91/02745. To date, no adverse reaction has been associated with physiological increases in plasma or cerebrospinal fluid levels of  $\beta$ -endorphins, enkephalins or substance P receptors.

The use of drugs to increase the production and/or secretion of opioid peptides may provide temporary relief, but uncontrollable drug metabolism and rough dosage eventually will overtax the "sick" neurons and their counterparts. Furthermore, the side effects of drugs are numerous and undesirable. Opioid peptides themselves and opioid peptide receptors have been administered as sedatives and analgesics, see U.S. patent No. 4,123,523, but the effects of such administrations are short-lived.

Xenogeneic tumor cells secreting  $\beta$ -endorphin have been transplanted into spinal cord cerebro-spinal fluid space of rats, producing analgesic effects. Saitoh et al., *Cell Trans.* 4 (Supp. 1): S13-7 (1995). The transplanted cells were reported to survive for one month, and *in vitro* studies indicated that the cells would secrete  $\beta$ -endorphin for one month. AtT-20 cells and AtT-20/hENK cells, which secrete  $\beta$ -endorphin and enkephalin, respectively, were implanted into mouse spinal subarachnoid space to investigate their use as a therapy for pain. Wu et al., *J. Neurosci.* 14(8): 4806

(1994); *J. Neural Transplant. Plast.* 4(1): 15 (1993). But these procedures are very invasive and therefore very dangerous, since they involve the transplantation of cells directly into cerebrospinal fluid or spinal subarachnoid space. Also, only a limited number of cells are transplanted, making the amount of opioid peptide provided by these methods limited.

A need therefore exists for a method of long term analgesia by supplying a peptide that binds to opioid receptors or that interferes with binding of substance P to its receptors *in vivo* over a long time period. Such a method would be useful for treating chronic pain and psychiatric conditions that involve abnormal perception, such as depression, chronic anxiety syndromes, paranoia, alcoholism, and drug addiction, and other diseases in which opioid neurons and substance P terminals play a role.

#### SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide a method of treating psychiatric conditions that involve abnormal perception, such as depression, chronic anxiety syndromes, paranoia, alcoholism, and drug addiction, chronic pain, and other diseases in which opioid neurons and substance P sensitive neurons play a role. It is also an object of the present invention to provide a composition for performing this method.

In accordance with this and other objects of the invention, there is provided a method of continuously supplying *in vivo* a peptide that can bind to opioid receptors or that can interfere with binding of substance P to its receptor comprising the steps of (a) transducing myogenic cells with DNA encoding the peptide, and (b) administering the transduced myogenic cells to a patient, such that the cells continuously produce the peptide. In one embodiment, the analgesic peptide is

selected from the group consisting of an opioid peptide, a polypeptide that binds substance P and a substance P analog. In one embodiment, the myogenic cells are selected from the group consisting of myoblasts, myotubes, and muscle cells. In another embodiment, the cells are transduced with DNA encoding multiple copy sequences of the peptide separated by cleavage sites. In another embodiment, the transduced cells are administered by intramuscular injection into a paraspinal muscle of the patient. In yet another embodiment, large chondroitin-6-sulfate proteoglycan or insulin is administered with the transduced myogenic cells. Co-administration of an immunosuppressant also is preferred in some embodiments.

The invention also provides a method of continuously supplying *in vivo* a naturally occurring analgesic peptide comprising the steps of (a) transducing myogenic cells with DNA containing a promoter for an endogenous structural gene encoding the peptide, and (b) administering the transduced myogenic cells to a patient, such that the cells continuously produce the peptide.

The invention further provides a composition for continuously supplying *in vivo* a peptide that binds an opioid receptor or that interferes with binding of substance P to its receptor, comprising the steps of (a) transducing myogenic cells that contain heterologous DNA and that express the peptide, and a pharmaceutically acceptable carrier. In one embodiment, the heterologous DNA comprises a gene encoding the peptide and a promoter. In another embodiment, the heterologous DNA comprises a promoter for an endogenous structural gene encoding the peptide. In another embodiment, the composition additionally comprises large chondroitin-6-sulfate proteoglycan or insulin.

Additional objects and advantages of the invention are set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the invention.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

It has been discovered that genetically transduced myogenic cells can be employed to provide a long-term, continuous supply of a peptide having analgesic activity. This method is useful for treating chronic pain as well as psychiatric conditions that involve abnormal perception, such as depression, chronic anxiety syndromes, paranoia, alcoholism, and drug addiction, and other diseases in which neurons that bind opioids and/or neurons that bind substance P play a role. Such conditions have not been treated heretofore by long-term administration of analgesic peptide *in vivo*.

Analgesic peptides suitable for the invention are peptides that bind opioid receptors or that interfere with binding of substance P to its receptor. Among these peptides are opioid peptides, polypeptides that bind substance P, and peptides that are substance P analogs. In this context, the phrase "polypeptide that binds substance P" denotes a peptide or protein that has affinity for substance P such as, for example, substance P receptor protein or a peptide or peptide analog derived from this receptor and that retain the ability to bind substance P. Such peptides and proteins bind substance P and thereby interfere with the binding of substance P with its receptor. The skilled artisan can test binding to substance P with an assay. Substance P analogs act as analgesics by interfering with binding between substance P and its receptor. For example, PCT application WO 91/02745, *supra*, discloses analogs that do not exhibit the natural activity of substance P but that act as competitive inhibitors of substance P.

In accordance with the invention, myogenic cells are transduced *ex vivo* so that they express at least one of the above-enumerated peptides, either while in cell culture, or after differentiation *in vivo*. Cells that

have been transduced with a gene encoding such a peptide are administered to the patient, for example, by injection into muscle or adipose tissue of the patient. The transduced cells can survive and grow in the recipient tissue. For example, cells injected into muscle tissue can form myotubes and mature into muscle fibers. Cells injected into adipose tissue can survive and be converted into fat cells. Transduced cells injected into both types of tissue can express the desired analgesic peptide continuously. The expressed peptide exits the cell and travels through the blood to other areas of the body, including the spinal cord and brain.

Myoblast transfer therapy (MTT) has been used to treat muscle weakness and degeneration and is a useful technique for administering cells that express an analgesic peptide. See U.S. patent No. 5,130,141, the contents of which are incorporated herein by reference. In accordance with this method, genetically normal myogenic cells are administered to a myopathic muscle of the patient, thereby increasing muscle function, locomotive patterns and respiratory function. Normal myoblast transfer therapy has been shown to produce the missing protein dystrophin for up to six years in Duchenne muscular dystrophy patients. Law et al., *Cell Transplantation* 6: 95-100 (1997).

Although early myoblast transfer studies used muscle as the recipient tissue, other tissues also can be used. For example, myoblasts can grow after their injection or surgical implantation into adipose tissue, as described by Satoh et al., *Transplantation Proceedings* 24: 3017-19 (1992).

Myoblasts have been transduced with genes for Factor IX, erythropoietin (EPO), and human growth hormone, and the Fas ligand to increase circulating levels of these proteins. Thompson, *Thromb. and Haemost.* 74(1): 45 (1995); Hamamori et al., *J. Clin. Invest.* 95: 1808 (1995), and *Human Gene Therapy* 5: 1349 (1994); Barr et

al., *Science* **254**: 1507 (1991); Dhawan et al., *Science*  
**254**: 1509 (1991); Lau et al., *Science* **273**: 109 (1996).  
The success of these methods has varied. According to  
Thompson (1995), for instance, preliminary data suggest  
5 that human myoblasts removed from the body survived less  
well in culture and progressively lost their ability to  
express factor IX. Lau et al. (1996), reports that  
expression of the Fas ligand was local and appeared to  
cease after 80 days. On the other hand, Hamamori et al.  
10 (1994) reports that the *in vivo* implantation of a stable,  
high level, EPO-producing muscle cell clone resulted in  
sustained high serum EPO levels for three months, and  
Dhawan et al. (1991) states that transduced myoblasts  
continued to secrete hGH after they differentiated into  
15 myotubes, with no difference in secretion levels between  
myoblasts and myotubes.

Transduced myoblasts have not been used previously  
to supply an analgesic peptide continuously *in vivo*,  
however. Furthermore, although gene therapy has been  
20 studied as a means of supplying opioid peptides *in vivo*,  
the transduced cells were injected directly into spinal  
cord, cerebro-spinal fluid or spinal subarachnoid space.  
Saitoh et al., *Cell Trans.* **4** (Supp. 1): S13-7 (1995); Wu  
et al., *J. Neurosci.*, **14**(8): 4806 (1994); Wu et al., *J.*  
25 *Neural Transplant. Plast.* **4**(1): 15 (1993). As discussed  
above, these methods are very invasive, only a limited  
number of cells are transplanted, and the transduced  
cells expressed the opioid peptides for only one month.  
In accordance with the present invention, by contrast,  
30 the transduced myoblasts are not injected into the  
central nervous system. Moreover, unlike the short-term  
expression of opioid peptides effected in conventional  
gene therapies, the present invention provides a  
continuous, long-term supply of opioid peptides which  
35 lasts, for example, up to at least six years. These  
aspects of the present invention represent distinct  
advantages that have not been appreciated.



Myogenic cells that are suitable for the present invention include myoblasts, myotubes, and muscle fiber cells. Myoblasts are particularly preferred, in accordance with one embodiment of the invention.

5 Myoblasts are mononuclear embryonic muscle cells that differentiate into multinucleated myotubes. Each nucleus of a myoblast contains over 100,000 genes, including genes for opioid peptides such as  $\beta$ -endorphins and enkephalins. Myoblasts divide extensively, migrate, fuse  
10 naturally to form syncytia, lose MHC-1 antigens soon after fusion, and constitute about 50% of the dry body weight of humans. Myoblasts are unusual in that they are capable of natural cell fusion among themselves and with mature muscle fibers. As a result of this fusion, a  
15 transduced myoblast transfers its nucleus and therefore all of its genes to the cell with which it fuses, which may be a genetically normal or an abnormal muscle cell.

Myogenic cells can be obtained from a patient to be treated, from a relative, or from another human or other  
20 animal donor. In a typical procedure, 1 to 2 grams of skeletal muscle is harvested from a donor. Myogenic cells also can be cultured or produced by cloning methods known to those skilled in the art as shown, for example, in U.S. patent No. 5,130,141.

25 In accordance with one embodiment of the invention, muscle cells from a human or animal donor are stimulated 0-3 days before harvesting to produce a reservoir of satellite cells that are myoblast reserves in mature muscles. The myogenic cells can be stimulated by, for  
30 example, injuring the cells with a number of needle probings, or by sonication.

In accordance with one embodiment of the invention, harvested cells are processed to obtain a pure culture of myoblasts. See Law et al. *Cell Transplant.* 1: 235  
35 (1992); *Cell Transplant.* 2: 485 (1993); *Muscle and Nerve* 11: 525-33 (1988). For example, a muscle biopsy is dissociated with 0.1% collagenase and 0.2% crude trypsin in phosphate buffered saline at pH 7.3. The mixture is

stirred for 45 minutes, with three changes of enzyme solution alternated with three changes of a neutralizing medium comprising 100 parts Dulbecco's modified Eagle's Medium (DMEM, Gibco) containing 0.37% NaHCO<sub>3</sub> and 4mM glutamine; 10 parts horse serum and 1% antibiotic-antimycotic.

Pursuant to one embodiment of the present invention, the harvested myogenic cells are transduced *ex vivo* with DNA encoding a peptide that either binds an endorphin receptor or that inhibits binding of substance P to its receptor. Peptides that are known to have suitable activity in this context are  $\beta$ -endorphin,  $\alpha$ -endorphin, gamma-endorphin, delta-endorphin, Met sup 5 (a five amino acid residue peptide with endorphin-like activity), active endorphin peptides comprising parts of the  $\beta$ -endorphin sequence, enkephalin, an NK-1 receptor, a polypeptide that binds substance P, or a substance P analog that competitively inhibits the binding of substance P to its receptor. The phrase "substance P analog" denotes a peptide that comprises the five carboxy-terminal amino acid sequence of substance P (-Phe-Phe-Gly-Leu-Met) and that binds to the substance P receptor, inhibiting substance P activity. See Payan, *Ann. Rev. Med.* 40: 341 (1989), and PCT application WO 91/02745.

Additional peptides can be found by kinetics experiments that reveal whether a given peptide either binds to an opioid receptor or competes for binding between substance P and its receptor. These experiments can be done routinely. See, for example, PCT application WO 92/16547.

DNA sequences useful for the invention are known or can be designed by those skilled in the art from known amino acid sequences of the peptides. For example, Saitoh *et al.*, *Cell Trans.* 4 (Supp. 1): S13-7 (1995), discloses a DNA sequence that codes for  $\beta$ -endorphin; Wu *et al.* (1993, 1994), *supra*, disclose sequences for  $\beta$ -endorphin and enkephalin; U.S. patent No. 4,123,523

discloses amino acid sequences of  $\beta$ -endorphin peptides; PCT application WO 92/16547 discloses a gene encoding the substance P receptor NK-1; Japanese patent document JP 3133998 discloses the amino acid sequence of a substance P receptor; and PCT application WO 91/02745 discloses the amino acid sequences of several substance P analogs, such as deletion and addition mutants of substance P.

In accordance with one embodiment of the invention, the DNA encodes a plurality of copies of a peptide that produces analgesia. In a preferred embodiment the peptide is an opioid peptide and regions of the DNA that code for multiple copies are separated by cleavage sites (see PCT application WO 96/17941). This embodiment can provide an amplified amount of a naturally occurring peptide.

The transduction of myogenic cells with a DNA sequence can be effected via known methods, such as those reported by Thompson (1995) and Hamamori et al. (1995), *supra*. Generally, a DNA construct is used that contains a promoter upstream of the structural gene that encodes the desired peptide. Suitable promoters are described, for example, in U.S. patent No. 5,618,698.

According to another embodiment of the present invention, the harvested myogenic cells are transduced *ex vivo* with a DNA containing a promoter that can link up with and function (*i.e.*, turn on or increase expression) with an endogenous gene within the nucleus of a myogenic cell. In this embodiment, DNA comprising a regulatory sequence, an exon and a splice donor are introduced into a cell by homologous recombination into the cell's genome at a preselected site. The introduction of this DNA results in the production of a new transcription unit in which the regulatory sequence, exon and splice donor site are operatively linked to the endogenous gene.

The introduction of DNA typically is followed by selection of cells that have received a promoter in a desired location, to turn on the desired gene. Applicable selection methodology is described, for

instance, in U.S. patent Nos. 5,641,670 and 5,272,071. Selection techniques also are described by Mansour et al., *Nature* 136: 348, 349 (1988). After selection, the cells which express the desired gene are cultured and then introduced into a patient.

The transduced myogenic cells are cultured to produce a sufficient quantity of cells for administration to the patient by any of a variety of methods known in the art. For example, see Law et al. (1988, 1992), *supra*. The amount of cells cultured will depend on the condition of the patient and the severity of the disease being treated. For example, from about 1 billion to about 100 billion myoblasts can be cultured for administration to a patient. In accordance with one embodiment of the invention, cells are cultured in the neutralizing medium described above, supplemented with two parts of chick embryo extract. Cells are fed fresh growth medium every two days, and are incubated in 7% CO<sub>2</sub> at 37°C for 35-40 days.

In accordance with one embodiment of the invention, the transduced cells are administered to the patient by intramuscular injection. Law et al., *Cell Transplant.* 1: 235 (1992); *loc. cit.* 2: 485 (1993); Law et al. *Exp. Neurol.*, *Transplant Proc.* 29: 2234 (1997). The amount of opioid peptides provided in accordance with the present invention can be controlled by selecting the number of muscles injected and the number of cells injected. In accordance with one embodiment of the invention, the direction of injection is controlled to optimize the number of transduced cells delivered to recipient muscle fibers. For example, injecting the administered cells diagonally through muscle fibers has been shown to maximize the resulting number of muscle fibers fused with administered cells.

Pursuant to another embodiment of the invention, transduced cells are administered to specific muscles which help target the cells to a location between laminae IV and V of the spinal cord. For example, the transduced

cells can be injected into paraspinal muscles or neck muscles, such as the levator scapulae. Although transduced myogenic cells administered anywhere in the body will secrete peptides that will travel through the blood and reach the spinal receptors, targeting the administration of the cells to paraspinal muscles or neck muscles that are in proximity to the spinal cord is expected to result in more peptides reaching the receptors more rapidly, thereby increasing the efficacy of the method.

The transduced cells also may be administered by surgical implantation into the patient. The cells can be implanted in, for example, adipose tissue.

In a further embodiment, the patient also is given an effective amount of an immunosuppressant to minimize rejection of the transduced cells. See U.S. patent No. 5,130,141 and Law et al. (1992, 1993), *supra*. For example, cyclosporin A, another immunosuppressant, or combinations of immunosuppressants, can be given in accordance with known procedures. Suitable dosage forms, dosage amounts and dosing schedules are known in the art. For example, cyclosporin A can be given orally in a daily dose of about 7 mg/kg body weight. A typical dosing schedule comprises giving the daily dose in two divided doses, and the patient's whole blood can be monitored to maintain a trough level of about 250 mg/ml cyclosporin A.

In accordance with one embodiment of the invention, fusion of the transduced myoblasts is facilitated by administration of large chondroitin-6-sulfate proteoglycan (LC6SP) as described in the above-cited U.S. application Serial No. 08/477,377. Trauma from injecting myoblasts into the extracellular matrix triggers the release of basic fibroblast growth factor and large chondroitin-6-sulfate proteoglycan. These released molecules stimulate myoblast proliferation. Increasing the level of large chondroitin-6-sulfate proteoglycan at the injection site facilitates myoblast fusion and proliferation. Accordingly, in accordance with one

embodiment of the invention, large chondroitin-6-sulfate proteoglycan preferably is administered with the transduced myoblasts.

In accordance with one embodiment of the invention, the large chondroitin-6-sulfate proteoglycan is under-sulphated. See Hutchison et al., *Devel. Biol.* 115: 78-83 (1986). Large chondroitin-6-sulfate proteoglycan is believed to be synthesized in an under-sulphated form pre-fusion, but becomes more highly sulphated post-fusion. *Id.* As used here, therefore, the phrase "under-sulphated large chondroitin-6-sulfate proteoglycan" denotes a degree of sulphation that is about the same as that observed in naturally occurring large chondroitin-6-sulfate proteoglycan from cells just before fusion. In accordance with this aspect of the invention under-sulphated large chondroitin-6-sulfate proteoglycan is administered at a concentration between about 5 $\mu$ M to about 5 mM. Chondroitin-6-sulfate can be administered together with the transduced cells, or can be given in a separate formulation as a separate injection.

Insulin also facilitates proliferation of myoblasts and promotes myotube development. In accordance with one aspect of the invention, therefore, insulin is administered with the transduced myocytes. For example about 0.2mM of insulin can be given, either as part of the same formulation as the cells, or as a separate formulation, given, for example, in a separate injection.

In accordance with one embodiment of the invention, undesirable effects from over-production of the desired peptide are regulated with agonists such as naloxone or SP-40,40. Pomeranz et al., *Altern. Thor. Health Med.* 2: 85 (1996); Choi-Miura et al., *Biol. Pharm. Bull.* 16: 228 (1993); Pomeranz et al., *Exp Neurol.* 54: 172 (1977). For example, if the endogenous level of the peptide becomes too high, naloxone or SP-40,40 can be administered to counteract the peptide's effects. Typical symptoms of over-production of an analgesic peptide include extreme drowsiness, low respiratory rate, cyanosis, low blood

pressure, symmetrical, pinpoint pupils, and depressed urine formation. A usual course of naloxone treatment involves giving small intravenous or intramuscular doses of naloxone (about 0.4 mg to about 0.8 mg). Symptoms frequently improve after the first dose, but can be repeated after 2-3 minutes, up to a total dose of about 10 mg.

As discussed above, the administration of transduced myogenic cells in accordance with the present invention provides a continuous, long-term supply of an analgesic peptide *in vivo*. The peptide travels from the site of synthesis such as from muscle or adipose tissue and reach sensory nerve endings, the spinal cord and brain, where it combines with nerve cell receptors to produce analgesia. Analgesia produced by the peptide is useful for treating chronic pain and psychiatric conditions that involve abnormal perception, such as depression, chronic anxiety syndromes, paranoia, alcoholism, and drug addiction, and other diseases in which opioid neurons and substance P terminals play a role. The continuous long-term supply of an analgesic peptide *in vivo* as a medical treatment offers a novel methodology of treating these conditions.

The invention also provides a composition that makes an analgesic peptide that binds to opioid receptors or interferes with binding of substance P to its receptor *in vivo*. In one embodiment, the composition comprises myogenic cells containing heterologous DNA coding for an analgesic peptide together with one or more pharmaceutically acceptable carriers.

Examples of suitable pharmaceutical carriers include diluents, solvents, buffers, and/or preservatives. An example of a pharmaceutically acceptable carrier is phosphate buffer that contains NaCl. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, salts, preservatives, buffers and the like, as described in REMINGTON'S PHARMACEUTICAL SCIENCES, 15th Ed. Easton: Mack Publishing

Co., pages 1405-1412 and pages 1461-1487 (1975), and THE NATIONAL FORMULARY XIV., 14th Ed. Washington: American Pharmaceutical Association (1975). Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyloleate. Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobials, anti-oxidants, chelating agents and inert gases. The pH and exact concentration of the various components of the binding composition are adjusted according to routine skills in the art. See GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS FOR THERAPEUTICS (7th ed.).

In accordance with one embodiment, the composition comprises transduced myogenic cells, large chondroitin-6-sulfate proteoglycan, and a pharmaceutically acceptable carrier.

In accordance with another embodiment, the composition comprises transduced myogenic cells, insulin, and a pharmaceutically acceptable carrier.

The embodiments of the invention are further illustrated through the following examples which show aspects of the invention in detail. These examples illustrate specific elements of the invention and are not to be construed as limiting the scope thereof.

***Example 1. Treatment of Patient Suffering from Depression by Injection into Muscle Tissue***

The skeletal muscles of a patient suffering from a psychiatric condition involving depression are stimulated by numerous needle probings to produce a reservoir of satellite myoblast cells. Three days later, the patient is placed under general anesthesia, and 2 g of skeletal muscle are harvested from the patient. The harvested muscle is processed to obtain a pure culture of myoblasts. The harvested muscle is dissected free of



skin and other tissue and the cells are dissociated with 0.1% collagenase and 0.2% crude trypsin in phosphate buffered saline at pH 7.3. The mixture is stirred for 45 minutes, with three changes of enzyme solution alternated with three changes of a neutralizing medium comprising 100 parts Dulbecco's modified Eagle's Medium (DMEM, Gibco) containing 0.37% NaHCO<sub>3</sub> and 4mM glutamine; 10 parts horse serum and 1% antibiotic-anti-mycotic.

These myoblasts are transduced with DNA containing a gene for enkephalin and a suitable promoter. The transduced myoblasts then are cultured in the neutralizing medium described above supplemented with 2 parts of chick embryo extract. The cells are fed fresh growth medium every 2 days, and are incubated in 7% CO<sub>2</sub> at 37°C for 40 days, when about 2 billion myoblast cells (progeny of the transduced myogenic cells) are present.

The patient again is placed under general anesthesia and the progeny of the transduced myogenic cells are injected intramuscularly, into paraspinal muscles of the patient. Within one week thereafter, the patient's symptoms should begin to ameliorate.

*Example 2. Treatment of Patient Suffering from Depression by Injection into Adipose Tissue*

Myoblasts are obtained and transduced as described in Example 1 to form about 10 billion progeny myoblast cells. The patient's breast tissue is anesthetized and the cells are injected into the anesthetized tissue. Within one week thereafter the patient's symptoms should begin to ameliorate.

*Example 3. Treatment of Patient Suffering from Alcoholism*

The skeletal muscles of a patient suffering from alcoholism are stimulated by sonication to produce a reservoir of satellite myoblast cells. Three days later, the patient is placed under general anesthesia, and 2 g of skeletal muscle are harvested from the patient. The

harvested muscle is processed to obtain a pure culture of myoblasts as described in Example 1 above.

These myoblasts are transduced with DNA containing a promoter for an endogenous  $\beta$ -endorphin gene. The transduced myoblasts then are cultured as described in Example 1 above, until 50 billion cells are obtained.

The patient is again placed under general anesthesia and the progeny of the transduced myogenic cells are injected into paraspinal muscles of the patient.

Within one week after the procedure, the patient's symptoms begin to be relieved.

**Example 4.      *Composition For Providing a Long-Term, Continuous Supply of Enkephalin In Vivo***

The following composition is provided:

1 billion myogenic cells transduced with DNA that codes for enkephalin; and a phosphate buffer containing NaCl and human serum albumen as a pharmaceutically acceptable carrier.

**Example 5.      *Composition For Providing a Long-Term, Continuous Supply of  $\beta$ -Endorphin In Vivo***

The following composition is provided:

1 billion myogenic cells transduced with DNA that codes for a promoter of a human endorphin gene; and water as a pharmaceutically acceptable carrier.

It will be apparent to those skilled in the art that various modifications and variations can be made to the processes and compositions of this invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.